Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Treatment with rosiglitazone reduces hyperinsulinemia and improves artery elasticity in type 2 diabetic patients.
Treatment with rosiglitazone reduces hyperinsulinemia and improves artery elasticity in type 2 diabetic patients.
Dr. Reuven Zimlichman, of Wolfson Medical Center, Holon, Israel, and colleagues conducted an open-label study to examine the effects of rosiglitazone on hyperinsulinemia and vascular elasticity in 52 patients with type 2 diabetes and at least one other cardiovascular risk factor. The subjects received 4 mg rosiglitazone for 6 months, which was titrated up to 8 mg after 3 months, if needed.
The researchers measured levels of insulin, C-peptide, and microalbuminuria/proteinuria at baseline and at the end of the study. They also evaluated glucose, chemistry, lipid profile, and hemoglobin A1C at baseline, 3 and 6 months, and assessed vascular compliance monthly.
Small artery elasticity increased significantly after treatment with rosiglitazone. Large artery elasticity also tended to increase toward the end of the study, but this increase was not statistically significant.
Decreases in both systolic blood pressure (144 mm Hg to 124 mm Hg) and diastolic blood pressure (80 mm Hg to 68 mm Hg) were observed, despite mild weight gain. Heart rate also decreased during treatment, though not significantly.
Systemic vascular resistance decreased significantly during treatment with rosiglitazone (p < .001), and significant decreases in plasma insulin were also observed (p = 0.0001).
The investigators concluded that the results also support the hypothesis that a decrease in hyperinsulinemia and improvement of insulin receptor sensitivity plays a significant role in the repair of tissue damage and their improvement has great potential in future therapeutic approach of prevention of end-organ damage. Am J Hypertens 2003;16:617-622.
==============================
"Diabetes in Control 10,000 Step Study 30 Million Steps and 15,000 Miles Later"
Because of the Diabetes In Control Study, more than 12000 patients have started the Step Program.
Have a program for your office.
More Information Then check out www.firststepprogram.com